Oxygen Biotherapeutics, Inc. Expands Board of Directors

DURHAM, N.C., Oct. 26 /PRNewswire-FirstCall/ -- Oxygen Biotherapeutics, Inc. today announced the expansion of the company’s board of directors with the addition of two new members. Appointed to the company’s board were Rene A. Eckert and The Honorable William A. Chatfield. With their addition, the company board now has eight members.

Rene Eckert was Chairman, CEO & Partner at Boehme Filatex Inc. of Reidsville, NC from 1981 to 2007. He started the specialty chemical company with two partners in 1981. They formed the company into a leading North American textile chemical corporation with subsidiaries in Canada and Mexico. In 2007 the corporation was sold to an international dyestuff company (Dystar).

About Oxygen Biotherapeutics, Inc.

Oxygen Biotherapeutics, Inc. is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine(TM). The company has developed a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte(TM)) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. Each of the product candidates is designed with advantages over currently marketed products in major markets including traumatic brain injury, sickle cell crisis, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes wounds and ulcers, and cosmetic applications which are being marketed under the Dermacyte name. More information is available at www.oxybiomed.com.

CONTACT: Abe Wischnia, Abe Wischnia & Associates, +1-619-795-2345

Web site: http://www.oxybiomed.com//

MORE ON THIS TOPIC